Severe Asthma Treatment Costs Burden Patients in south Korea

SEOUL, South Korea⁤ (2025-05-05) — While treatments exist to mitigate⁣ the effects ⁣of severe⁢ asthma, many patients face financial ⁢barriers that prevent them from continuing potentially life-improving therapies. Experts suggest that extending health insurance benefits to ⁣include biologic therapies is crucial for ensuring stable treatment access.

World Asthma Day Highlights Growing Concern

Celebrated annually on the first Tuesday of May, World Asthma Day, as designated by the Global initiative for Asthma (GINA), aims to raise⁤ awareness about this chronic respiratory disease. Asthma claims over 450,000 lives globally each year, and its prevalence ‍is‍ on ‍the rise in South korea. Data from the National Health Insurance Corporation indicates a nearly 20% year-over-year increase in asthma ⁢patients⁤ within the contry. Of⁣ particular concern is the prevalence of severe asthma, wich, at 13.9%,⁤ more than doubles the global average of 6.1% reported by GINA.

Understanding Asthma and its ‍Severity

Asthma is characterized as a chronic inflammatory condition affecting the respiratory system.Inflammation causes the bronchial tubes to narrow, leading to recurring episodes of wheezing, ‍coughing, shortness of breath, and chest tightness. Symptoms ⁣can be triggered by external irritants⁢ and ⁤exacerbated by internal‍ factors such as stress and physical exertion. In some individuals,asthma can ‍progress to a severe form,substantially⁣ impacting their quality of life.

biologic Therapies Offer Hope, But Accessibility Lags

Dr. Moon Ji-yong, a professor specializing in respiratory allergies at Konkuk University Hospital, noted the challenges‍ in managing ⁣symptoms for⁤ patients with severe asthma. “Severe asthma patients often find it ⁤tough to achieve adequate symptom control,” Moon said. “The recent introduction of various biologic therapies in South Korea is expanding‍ treatment possibilities.”

One such biologic, Dupixent (dupilumab), has demonstrated meaningful efficacy in treating severe asthma. A sub-analysis of global clinical trials focusing‍ on Korean patients ⁢revealed an 87% reduction in the annual rate of severe asthma exacerbations among those treated with Dupixent compared to a placebo. Moreover, patients with elevated blood eosinophil levels (150 or greater) experienced up to a 94% decrease in exacerbation incidence.

The Cost ‍Hurdle: Affordability Concerns

Despite its effectiveness, accessibility to Dupixent remains a significant challenge. While the Ministry of Food and Drug Safety approved Dupixent for severe⁢ asthma treatment in ‍April 2020, it is not currently covered by national ⁤health insurance.⁢ This‍ lack of coverage places a⁣ significant financial burden on patients,making it difficult for many ⁢to‍ sustain treatment despite its proven benefits.

Members of online lung disease support groups have reported that the medication costs nearly 700,000 won (approximately $530 USD) per month. While they acknowledge the improved breathing and enhanced quality of life resulting from the treatment, the expense⁤ is a major concern.

Expert Calls for Increased Access

Professor Moon emphasized the critical need for health insurance coverage, stating ‍that “patients⁤ are forgoing effective treatment⁢ due to the financial strain caused by Dupixent not being covered.” ⁣Expanding access to these therapies is essential to improving outcomes⁤ for individuals with‍ severe asthma in South ⁣Korea.

Severe Asthma Treatment Costs in South Korea: Your Questions Answered

What is Asthma?

Asthma is a chronic inflammatory condition affecting⁤ the⁣ respiratory system. Inflammation causes the bronchial ⁣tubes to narrow, leading ⁢to‍ recurring⁣ episodes of wheezing, coughing, shortness of breath, and chest tightness.

What are the ⁣different severities of Asthma?

Asthma symptoms can range in severity for⁤ each individual. Symptoms can be triggered by external irritants and ⁣exacerbated by internal factors such as stress and physical exertion.

What is ⁣Severe Asthma?

In⁢ some individuals, asthma can progress to a severe form, substantially⁤ impacting their quality of life.Severe asthma often presents significant challenges in symptom management for patients.

What are the current challenges in treating Severe Asthma ‍in South Korea?

While treatments exist to mitigate the effects of severe asthma,many⁤ patients face financial barriers ⁢that prevent them from continuing potentially life-improving therapies⁣ in South Korea.

Why is World ⁤Asthma⁤ Day vital?

World Asthma Day, celebrated annually on the first Tuesday of May, aims to raise awareness about this chronic respiratory disease. ⁤It’s⁢ designated by⁤ the global initiative for Asthma (GINA).

How prevalent is asthma in South Korea?

Asthma prevalence is on the rise in⁢ South Korea. Data from the National Health Insurance Corporation ‍indicates a nearly ⁣20% year-over-year increase in asthma patients in the country.

How does the prevalence of severe asthma⁢ in South Korea compare to the global average?

Of particular concern is the prevalence of severe asthma, ⁤which, at 13.9%, ⁤more than doubles the global average of 6.1% reported by GINA.

What are Biologic Therapies for Severe ⁤asthma?

Biologic ⁣therapies are a newer class of treatments offering hope for⁢ managing⁣ severe⁣ asthma. these therapies target specific parts of the immune system that ⁣cause⁢ airway inflammation.

What is ⁢Dupixent and how does it work?

Dupixent (dupilumab) is one specific biologic ‍therapy that has shown meaningful efficacy in treating severe asthma. It’s designed to reduce inflammation⁣ in the airways.

what‍ are the benefits ⁢of Dupixent for severe ⁤asthma?

A sub-analysis of ⁢global clinical trials focusing on Korean⁣ patients revealed an 87% reduction in the annual⁢ rate ⁢of severe asthma exacerbations among those treated with⁢ Dupixent compared⁤ to a placebo. Patients with elevated blood eosinophil levels (150 or greater) experienced up to a 94% decrease in exacerbation incidence.

Is Dupixent accessible to patients in South Korea?

Despite it’s effectiveness, accessibility to Dupixent remains a ⁤significant challenge. While the Ministry of Food and Drug Safety approved Dupixent for severe asthma treatment in April 2020, ⁣it is not currently covered⁣ by⁣ national health ⁤insurance.

What is the cost of Dupixent ‍in ⁤South Korea?

The lack of health insurance coverage ⁤places a significant financial burden on patients. Members of online lung disease support groups have reported‍ that the medication costs nearly ⁣700,000 won⁣ (approximately $530 USD) per⁣ month.

Why is health insurance coverage for biologic therapies‍ like Dupixent so important?

Professor Moon⁢ emphasized the critical⁤ need for health insurance coverage, ⁤stating that “patients are forgoing effective treatment due to the financial strain caused by Dupixent not⁤ being covered.” Expanding access to these therapies is essential to improving‍ outcomes for individuals with severe asthma in South Korea.

What can be ‍done⁢ to improve access to severe asthma treatments in South Korea?

experts suggest that extending health insurance benefits to include biologic therapies is crucial for ensuring stable treatment access.⁢ Increased ⁢coverage can help patients afford life-improving ⁣medications like Dupixent and improve overall health outcomes.